ERBB2 and breast cancer: Several of the drugs identified here are known to have anti-cancer effects, and one, fulvestrant, is already used to treat hormone receptor-positive, HER2-negative metastatic BC in post-menopausal women59, bolstering our confidence in the other recommended drugs.